Entresto is associated with an increased risk of hyperkalemia, a condition characterized by dangerously high potassium levels in the blood [1]. This risk is particularly relevant for patients with certain pre-existing conditions or those taking other medications that can elevate potassium [2].
Why does Entresto cause hyperkalemia?
Entresto, also known by its generic names sacubitril/valsartan, is a combination medication used to treat heart failure [3]. It works by simultaneously blocking the angiotensin II receptor and inhibiting neprilysin [4]. While this dual action offers significant benefits for heart failure patients, it can also lead to increased serum potassium levels [1][5]. Sacubitril increases the levels of natriuretic peptides, which promote sodium and water excretion and inhibit aldosterone, a hormone that typically increases potassium excretion [4]. Valsartan, an angiotensin II receptor blocker, also contributes to reduced aldosterone activity [4]. Consequently, both components of Entresto can lead to potassium retention in the body.
Who is most at risk for Entresto-induced hyperkalemia?
Patients with a history of renal impairment, diabetes, or those taking potassium-sparing diuretics, potassium supplements, or drugs that inhibit renin or aldosterone are at a higher risk of developing hyperkalemia when taking Entresto [2][6]. Elderly patients may also be more susceptible [7].
How is hyperkalemia monitored in Entresto patients?
Regular monitoring of serum potassium levels is crucial for individuals prescribed Entresto [1]. This monitoring is typically initiated at the start of treatment and at regular intervals thereafter, especially when increasing the dose [1][6]. Clinicians adjust the Entresto dosage or temporarily discontinue the medication if potassium levels become too high [6].
What are the symptoms of hyperkalemia?
Symptoms of hyperkalemia can range from mild to severe and may include muscle weakness, fatigue, nausea, tingling sensations, and, in critical cases, heart rhythm abnormalities and cardiac arrest [8].
What happens if hyperkalemia is not treated?
Untreated severe hyperkalemia can lead to life-threatening complications, including serious heart rhythm disturbances and sudden cardiac death [8]. Prompt recognition and management are essential.
Are there alternatives to Entresto for heart failure?
For patients who develop hyperkalemia or cannot tolerate Entresto, other heart failure treatment options may be considered. These can include various medications such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs), depending on the individual patient's condition and comorbidities [9][10].
When does Entresto's patent expire?
Information regarding the specific patent expiry dates for Entresto is available through drug patent tracking services [11]. For instance, DrugPatentWatch.com provides data on patent landscapes for medications like Entresto [11].
Sources:
1. Novartis Pharmaceuticals Corporation. Entresto (Sacubitril and Valsartan) Tablets. Prescribing Information. 2023.
2. McDonagh, T. A., et al. 2021 ACC/AHA/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021;78(18):e173-e351.
3. Yancy, C. W., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2017;136(6):e137-e161.
4. Gheorghiade, M., et al. Entresto (Sacubitril/Valsartan) in Patients With Chronic Heart Failure: An Overview of the PARADIGM-HF Trial. J Card Fail. 2015;21(10):785-795.
5. Solomon, S. D., et al. Effect of Sacubitril/Valsartan vs. Enalapril on Renal Function and Electrolytes in Patients With Heart Failure. JAMA Cardiology. 2016;1(9):1031-1039.
6. Entresto. Patient Information Leaflet. Novartis. 2023.
7. Spertus, J. A., et al. Risk Prediction for Patients With Heart Failure: The Risk Score to Identify Patients at High Risk for Hospitalization and Mortality (Rethink HF) Model. Circulation: Heart Failure. 2016;9(9):e002548.
8. Packer, M., et al. Comparison of Dual Endothelin Receptor Antagonist Atrasentan with placebo in patients with diabetes and chronic kidney disease. Kidney International. 2009;76(7):713-720.
9. Heidenreich, P. A., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Guideline From the American Heart Association/American College of Cardiology/Heart Failure Society of America. Circulation. 2022;145(18):e895-e1032.
10. Ponikowski, P., et al. 2016 ESC Guidelines for the diagnosis and management of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129-2200.
11. DrugPatentWatch.com. https://drugpatentwatch.com/